Accession Number: | 0000891092-18-005399 |
Date: | 2018-07-18 |
Issuer: | ACORDA THERAPEUTICS INC (ACOR) |
Original Submission Date: |
SCOPIA CAPITAL MANAGEMENT LP
152 WEST 57TH STREET, 33RD FLOOR
NEW YORK, NY 10019
SCOPIA MANAGEMENT, INC.
152 WEST 57TH STREET, 33RD FLOOR
NEW YORK, NY 10019
SIROVICH MATTHEW
152 WEST 57TH STREET, 33RD FLOOR
NEW YORK, NY 10019
MINDICH JEREMY
152 WEST 57TH STREET, 33RD FLOOR
NEW YORK, NY 10019
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2018-07-18 | S | 21,460 | d | $28.97 | 7,315,071 | indirect | f1,f2,f3 | |
COMMON STOCK | 2018-07-19 | S | 65,700 | d | $29.15 | 7,249,371 | indirect | f1,f2,f3 | |
COMMON STOCK | 2018-07-20 | S | 21,580 | d | $29.05 | 7,227,791 | indirect | f1,f2,f3 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | this form 4 is filed jointly by scopia capital management lp ("scopia management"), scopia management, inc. ("scopia inc."), matthew sirovich and jeremy mindich. the securities reported in this form 4 are held in the accounts of several private investment funds, including scopia long llc, scopia windmill fund lp, scopia international master fund lp, scopia px llc, scopia px international master fund lp, scopia partners llc, scopia long international master fund lp, scopia long qp llc, scopia health care llc, scopia health care international master fund lp, scopia lb llc and scopia lb international master fund lp (together, the "investment vehicles") for which scopia management serves as the investment manager. each of the investment vehicles individually holds less than 10% of the outstanding shares of common stock of acorda therapeutics, inc. (the "issuer"). |
f2 | (continued from footnote 1) scopia management, as the investment manager of the investment vehicles, may be deemed to indirectly beneficially own the shares of common stock of the issuer held directly by the investment vehicles because scopia management has voting and investment power over such securities. in addition, scopia inc., as general partner of scopia management, and matthew sirovich and jeremy mindich, as managing directors of scopia inc., may be deemed to indirectly beneficially own the shares of common stock of the issuer held directly by the investment vehicles because each of scopia inc., mr. sirovich and mr. mindich may be deemed to exercise voting and investment power over such securities. further, scopia management, scopia inc. and messrs. sirovich and mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the investment vehicles due to scopia management's right to receive performance-based allocations. |
f3 | each of scopia management, scopia inc. and messrs. sirovich and mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of scopia management, scopia inc. or messrs. sirovich and mindich is the beneficial owner of such securities for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose. |